Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

U.S. stocks ended the week lower as pressure from rates and commodities weighed on risk appetite. The Dow Jones Industrial Average (DJIA) fell 0.36...

The Week That Was, The Week Ahead: Macro and Markets, Feb. 1

Annovis Bio ( ($ANVS) ) has shared an announcement. On January 28, 2026, Annovis Bio, Inc. held a webinar, supported by a prepared presentation tha...

Annovis Bio Hosts Regulation FD Investor Information Webinar

The Trump administration has announced the names of 15 drugs targeted for Medicare price negotiations for 2028. The new list of branded medications...

CMS Names Pfizer, Eli Lilly, and AbbVie Drugs for Third Medicare Price Talks

In a report released on January 23, Stephan Lingnau from Erste Group maintained a Buy rating on Novartis AG. The company’s shares closed today at C...

Erste Group Sticks to Their Buy Rating for Novartis AG (NOVN)

Swiss drugmaker Novartis ($NVS) has said it expects to reduce its U.S. tariff exposure to a minimum by halfway through this year due to its agreeme...

Novartis Stock (NVS) Holds on Upbeat View of Tariff Exposure amid U.S.-EU Tension

A new U.S.-EU trade war is brewing and could leave several European stocks across pharmaceutical, auto, and fashion possibly exposed. What’s Happen...

These European Stocks Could Be in the Firing Line in Trump’s Greenland Tariff War

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novartis AG, with a price target of CHF125.00. Papadak...

Deutsche Bank  Reaffirms Their Buy Rating on Novartis AG (NOVN)

Bank of America Securities analyst Allen Lutz maintained a Buy rating on Envista Holdings today and set a price target of $28.00. Lutz covers the H...

Envista Holdings (NVST) Receives a Buy from Bank of America Securities

In a report released yesterday, Shirley Chen from Barclays maintained a Hold rating on Novartis AG. The company’s shares closed yesterday at CHF114...

Barclays Sticks to Its Hold Rating for Novartis AG (NOVN)

In a report released today, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on Envista Holdings, with a price target of $26.00. Ac...

Envista Holdings (NVST) Gets a Buy from Evercore ISI

Tempus AI’s ($TEM) preliminary results show its total contract value (TCV) surpassed $1.1 billion, marking the highest level in its history. The up...

Tempus AI (TEM) Tops $1.1B in Total Contract Value as Pharma Demand for AI Tools Surges

Johnson & Johnson ($JNJ) reached a significant agreement with the Trump administration to lower drug prices for Americans while securing exemptions...

Johnson & Johnson Wins Tariff Relief from Trump in a Drug Pricing Deal

In a report released yesterday, Matthew Weston from UBS maintained a Hold rating on Novartis AG. The company’s shares closed today at CHF111.52. We...

Novartis AG (NOVN) Gets a Hold from UBS

The race for obesity-drug market share was one key highlight for Big Pharma in 2025. However, data shows the Big Pharma rally seen in 2025 is more ...

LLY, JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze

In a report released today, Shirley Chen from Barclays upgraded Novartis AG to a Hold, with a price target of CHF120.00. According to TipRanks, Che...

Novartis AG (NOVN) was upgraded to a Hold Rating at Barclays

Berenberg Bank analyst Luisa Hector maintained a Hold rating on Novartis AG yesterday and set a price target of CHF92.00. The company’s shares clos...

Berenberg Bank Sticks to Their Hold Rating for Novartis AG (NOVN)

In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis, with a price target of $116.00. The company...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVS	$150.04	-0.66%	2.73M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVS	$150.04	-0.7%	2.73M
3
4
5
6

NVS

NVS

No Data Available

Get Novartis AG Data in Excel

Get Novartis AG Data in Excel